Telratolimod
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527804

CAS#: 1359993-59-1

Description: Telratolimod, also known as MEDI-9197, 3M-052, is a toll-like receptor 7 (TLR-7) and toll-like receptor 8 (TLR-8) agonist potentially for the treatment of solid tumors. MEDI-9197 is an IRM bearing a C18 lipid moiety and designed for slow dissemination from the site of application. MEDI-9197 drives a strong Th1 response to hemagglutinin and serum neutralization of viable H1N1 A/Puerto Rico/8/34 virus in the absence of circulating TNFα or the induction of Th1 cytokines.

Chemical Structure

img
Telratolimod
CAS# 1359993-59-1
Instruction

Theoretical Analysis

MedKoo Cat#: 527804
Name: Telratolimod
CAS#: 1359993-59-1
Chemical Formula: C36H59N5O2
Exact Mass: 593.47
Molecular Weight: 593.901
Elemental Analysis: C, 72.81; H, 10.01; N, 11.79; O, 5.39

Price and Availability

Size Price Availability Quantity
1mg USD 350 2 Weeks
5mg USD 950 2 Weeks
10mg USD 1650 2 Weeks
Bulk inquiry

Synonym: MEDI-9197; MEDI 9197; MEDI9197; 3M-052; 3M 052; 3M052; Telratolimod;

IUPAC/Chemical Name: N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)stearamide

InChi Key: RRTPWQXEERTRRK-UHFFFAOYSA-N

InChi Code: InChI=1S/C36H59N5O2/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-18-19-27-33(42)38-28-22-23-29-43-41-32(26-6-4-2)40-34-35(41)30-24-20-21-25-31(30)39-36(34)37/h20-21,24-25H,3-19,22-23,26-29H2,1-2H3,(H2,37,39)(H,38,42)

SMILES Code: CCCCCCCCCCCCCCCCCC(NCCCCON1C(CCCC)=NC2=C1C3=CC=CC=C3N=C2N)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 593.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine. 2011 Jul 26;29(33):5434-42. doi: 10.1016/j.vaccine.2011.05.061. PubMed PMID: 21641953.

2: Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 1;193(9):4722-31. doi: 10.4049/jimmunol.1401160. PubMed PMID: 25252955; PubMed Central PMCID: PMC4201984.

3: Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12. doi: 10.1186/2051-1426-2-12. PubMed PMID: 24982761; PubMed Central PMCID: PMC4075973.

4: Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG. Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. PubMed PMID: 27847326; PubMed Central PMCID: PMC5176129.